NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
Clinical Trials
14 trialsNCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT02366728 2023-06-08
ELEVATE
Duke University
Phase 2 Completed
NCT02513329 2023-06-05
Stellate Ganglion Block (SGB) For Women for Breast Cancer
Northwestern University
Phase 2 Completed
NCT03776721 2021-06-25
Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting
Odense University Hospital
Phase 2 Completed
NCT00866970 2020-07-09
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
CSL Behring
Phase 2 Completed
NCT02705352 2020-03-09
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Massachusetts Eye and Ear Infirmary
Phase 2 Completed
NCT02525718 2019-08-14
Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction
Northwestern University
Phase 2 Completed
NCT03557255 2018-06-14
Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries
National Cancer Institute, Egypt
Phase 2 Completed
NCT00854308 2017-03-31
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Genentech, Inc.
Phase 2 Completed
NCT01205503 2016-02-24
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
University of Kentucky
Phase 2 Completed
NCT01386242 2016-01-05
Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2 Completed
NCT00459654 2014-06-25
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Bayer
Phase 2 Completed